HeartFlow Clinical Evidence Summary
Bibliography of Published Literature
Category III CPT Codes for FFRCT
Template – Appeal for Investigational or Experimental Denial
Template – Appeal for No Prior Authorization Denial
Aetna Medical Policy
AIM Appropriate Use Criteria: Imaging of The Heart
Anthem Medical Policy
BCBS of Alabama
BCBS of Arizona Medical Coverage Guidelines
BCBS of Florida Medical Policy
BCBS of Kansas City Medical Policy
BCBS of Kansas Medical Policy
BCBS of Louisiana Medical Policy
BCBS of Massachusetts Medical Policy
BCBS Nebraska Medical Policy
BCBS of North Carolina Medical Policy
BCBS of Rhode Island
BCBS of South Carolina Medical Policy
BCBS of Tennessee Medical Policy
BCBS of Western New York
Blue Cross of Idaho Medical Policy
Blue Shield of California Medical Policy
eviCore Cardiac Imaging Policy
HCSC Medical Policy (BCBS Illinois, Montana, New Mexico, Oklahoma, and Texas)
Highmark BCBS Medical Policy
Horizon BCBS of New Jersey Medical Policy
Independence Blue Cross Medical Policy
NICE Guidance on HeartFlow FFRCT
Priority Health Medical Policy
If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.
HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用することを目的としています。
さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.
The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.
For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.
Please apply for research grants through our online submission form.
Executive Vice President and Chief Medical Officer
Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.
He received his A.B. from Harvard College and his M.D. from Harvard Medical School.